1223 results about "Transcriptional factor" patented technology

The invention is directed to a method for accelerating the cell cycle by delivering to a cell an effective amount of electromagnetic energy. The invention also provides a method for activating a cell cycle regulator by delivering to a cell an effective amount of electromagnetic energy. Also provided by the invention is a method for activating a signal transduction protein; a method for activating a transcription factor; a method for activating a DNA synthesis protein; and a method for activating a Receptor. A method for inhibiting an angiotensin receptor as well as a method for reducing inflammation also are provided by the present invention. The invention also is directed to a method for replacing damaged neuronal tissue as well as a method for stimulating growth of administered cells.

This invention relates to a method for prevention and treatment of Atherosclerosis, Peripheral Vascular Disease, Coronary Artery Disease, and age-related disorders including Osteoporosis, Arthritis, Type II Diabetes, Dementia and Alzheimer's disease in a subject comprising administering to said subject a therapeutically effective dosage of each component or combination of statins, bisphosphonates, cholesterol lowering agents or techniques, interleukin-6 inhibitor/antibody, interleukin-6 receptor inhibitor/antibody, gp130 protein inhibitor/antibody, tyrosine kinases inhibitors/antibodies, STAT transcription factors inhibitors/antibodies, altered IL-6, partial peptides of IL-6 or IL-6 receptor, or SOCS (suppressors of cytokine signaling) protein, or a functional fragment thereof, administered separately, in sequence or simultaneously. Inhibition of the signal transduction pathway for Interleukin 6 mediated inflammation is key to the prevention and treatment of atherosclerosis, peripheral vascular disease, coronary artery disease, aging and age-related disorders including osteoporosis, type 2 diabetes, dementia and some forms of arthritis and tumors. Inhibition of Interleukin 6 mediated inflammation may be achieved indirectly through regulation of endogenous cholesterol synthesis and isoprenoid depletion or by direct inhibition of the signal transduction pathway including interleukin-6 inhibitor/antibody, interleukin-6 receptor inhibitor/antibody, gp130 protein inhibitor/antibody, tyrosine kinases inhibitors/antibodies, STAT transcription factors inhibitors/antibodies, altered IL-6, partial peptides of IL-6 or IL-6 receptor, or SOCS (suppressors of cytokine signaling) protein, or a functional fragment thereof. Said method for prevention and treatment of said disorders is based on inhibition of Interleukin-6 inflammation through regulation of cholesterol metabolism, isoprenoid depletion and inhibition of the signal transduction pathway.

Transcription factor polynucleotides and polypeptides incorporated into nucleic acid constructs, including expression vectors, have been introduced into plants and were ectopically expressed. Transgenic plants transformed with many of these constructs have been shown to be more resistant to disease (in some cases, to more than one pathogen), or more tolerant to an abiotic stress (in some cases, to more than one abiotic stress). The abiotic stress may include, for example, salt, hyperosmotic stress, water deficit, heat, cold, drought, or low nutrient conditions.

The compound represented by the general formula (I):

• • wherein, a fused ring AB represents a 5- to 10-membered fused heterocyclic ring; R¹ represents (1) a hydrogen atom, (2) a halogen atom, (3) a cyano group, (4) an oxo group, (5) an optionally protected hydroxyl group, (6) an optionally protected carboxyl group, (7) an optionally protected amino group, (8) a cyclic group which may have a substituent (s), (9) an aliphatic hydrocarbon group which may have a substituent (s), or (10) an optionally protected thiol group; n represents 0 or an integer of 1 to 8; provided that n represents an integer of not less than 2, plural R¹ are the same or different; a salt thereof, a solvate thereof or a prodrug thereof has a kinase (especially c-Jun N-terminal kinase) inhibitory activity and an inhibitory activity of a function of AP-1 as a transcription factor, it is useful as a preventive and/or therapeutic agent for a for example, a diabetes of metabolic disease, etc., a rheumatoid arthritis of inflammatory, etc.

The present invention provides a stress responsive promoter. The environmental stress responsive promoter of the present invention comprises DNA of the following (a), (b) or (c): (a) DNA consisting of any nucleotide sequence selected from SEQ ID NOS: 1 to 90; (b) DNA consisting of a nucleotide sequence comprising a deletion, substitution or addition of one or more nucleotides relative to any nucleotide sequence selected from SEQ ID NOS: 1 to 90, and functioning as an environmental stress responsive promoter; and (c) DNA hybridizing under stringent conditions to DNA consisting of any nucleotide sequence selected from SEQ ID NOS: 1 to 90, and functioning as an environmental stress responsive promoter.

Novel DNA constructs are provided which may be used as molecular probes or inserted into a plant host to provide for modification of transcription of a DNA sequence of interest in cotton fiber, particularly in very early fiber development. The DNA constructs comprise a cotton fiber transcriptional initiation regulatory region associated with a gene which is expressed in cotton fiber.

The invention discloses three novel cotton ABF/AREB/ABI5/DPBF type transcription factors GhABF2, GhABF3 and GhABI5, and coding genes and application thereof. Amino acid sequences of the GhABF2, GhABF3 and GhABI5 are shown as SEQ ID NO: 2, 5 and 8 respectively. Nucleotide sequences of the coding genes GhABF2, GhABF3 and GhABI5 are shown as SEQ ID NO: 1, 4 and 7 respectively. The invention also discloses the structural characteristics on genomic deoxyribonucleic acid (DNA) and a ribonucleic acid (RNA) editing law of reading frame regions of the coding genes GhABF2, GhABF3 and GhABI5. The invention also discloses the cotton expression characteristics and yeast expression characteristics of the three genes and the characteristic that the three genes can improve the drought resistance of arabidopsis thaliana. The genes provide gene resources for culturing a plant variety resistant to abiotic stress, and have great significance for improving the abiotic stress resistance of plants.

The invention provides a method for preparing induced pluripotent stem cells. A combination of 4 small molecule compounds (HDAC inhibitor, GSK3-beta inhibitor, TGF-beta inhibitor and H3K4 demethylation inhibitor) or at least two of them (such as GSK3 -beta inhibitor and TGF-beta inhibitor), can induce induced pluripotent stem cells (iPS cells) under the condition of introducing only one transcription factor (Oct4).

The invention discloses application of panax japonicus transcription factor gene PjWRKY1, namely, application in improving the expression quantity of key enzyme genes in the biological synthesis of panax japonicus saponins, and increasing the content of saponins in panax japonicus callus. The nucleotide sequence of the PjWRKY1 gene is shown as SEQ ID NO: 1, and WRKY transcription factors are coded. Through the adoption of functional genomics and techniques related to metabolic engineering, a panax japonicus PjWRKY1 transcription factor is proved to have the effect of positively regulating the biological synthesis of panax japonicus saponins; when the panax japonicus PjWRKY1 transcription factor gene disclosed by the invention is established on a plant expression vector and transferred into the panax japonicus callus for over expression, the expression quantity of the key enzyme genes in the synthetic route of panax japonicus saponins is increased, and the yield of panax japonicus saponins is increased.

The invention discloses a soybean MYB (v-myb avian myeloblastosis viral oncogene homolog) transcription factor as well as a coding gene and an application thereof, belonging to the technical field of the gene engineering. The MYB provided by the invention has the name of GmMYB12B2, and the amino acid residue sequence of the MYB is disclosed by SEQ ID No.2; and the nucleotide sequence of the coding gene of the soybean MYB transcription factor is disclosed by SEQ ID No.1. The gene disclosed by the invention has an important meaning on the flavonoid metabolism of improved plants, and especially has an important meaning on culturing high-isoflavone soybean varieties.

The present invention relates generally to the field of molecular biology and concerns a method for enhancing various economically important yield-related traits in plants. More specifically, the present invention concerns a method for enhancing yield-related traits in plants by modulating expression in a plant of a nucleic acid encoding an ASPAT (Asparatate AminoTransferase) polypeptide. The present invention also concerns plants having modulated expression of a nucleic acid encoding an ASPAT polypeptide, which plants have enhanced yield-related traits relative to control plants. The invention also provides hitherto unknown ASPAT-encoding nucleic acids and constructs comprising the same, useful in performing the methods of the invention. Furthermore, the present invention relates generally to the field of molecular biology and concerns a method for increasing various plant yield-related traits by increasing expression in a plant of a nucleic acid sequence encoding a MYB91 like transcription factor (MYB91 ) polypeptide. The present invention also concerns plants having increased expression of a nucleic acid sequence encoding an MYB91 polypeptide, which plants have increased yield- related traits relative to control plants. The invention additionally relates to nucleic acid sequences, nucleic acid constructs, vectors and plants containing said nucleic acid sequences. Even furthermore, the present invention relates generally to the field of molecular biology and concerns a method for improving various plant growth characteristics by modulating expression in a plant of a nucleic acid encoding a GASA (Gibberellic Acid-Stimulated Arabidopsis). The present invention also concerns plants having modulated expression of a nucleic acid encoding a GASA, which plants have improved growth characteristics relative to corresponding wild type plants or other control plants. The invention also provides constructs useful in the methods of the invention. Yet furthermore, the present invention relates generally to the field of molecular biology and concerns a method for enhancing various economically important yield-related traits in plants. More specifically, the present invention concerns a method for enhancing yield-related traits in plants by modulating expression in a plant of a nucleic acid encoding an AUX/IAA (auxin/indoleacetic acid) polypeptide. The present invention also concerns plants having modulated expression of a nucleic acid encoding IAA polypeptide, which plants have enhanced yield-related traits relative to control plants. The invention also provides constructs comprising AUX/IAA-encoding nucleic acids, useful in performing the methods of the invention.

The invention provides an MYB transcription factor CmMYB6 implicated in chrysanthemum petal anthocyanin biosynthesis regulation. The coding region sequence of the MYB transcription factor CmMYB6 contains 765 nucleotides. A CmMYB6 amino acid sequence contains a conserved R2R3 MYB domain, a [D/E]Lx2[R/K]x3Lx6Lx3R motif and an ANDV motif exist in the R3 domain, the [D/E]Lx2[R/K]x3Lx6Lx3R motif can interact with bHLH, and the ANDV motif is the characteristic motif of the MYB transcription factor implicated in anthocyanin biosynthesis regulation. The gene expression of CmMYB6 rises in the petal growth process and is significantly and positively correlated with anthocyanin synthesis the CmMYB6 can induce the activity of synthesis of a key gene CmDFR promoter from anthocyanin, and the CmMYB6 has substantially enhanced induction usefulness and can strongly induce accumulation of tobacco leaf anthocyanin during cooperative expression of the CmMYB6 and MrbHLH1. The MYB transcription factor can be used in transcription regulation of plant anthocyanin biosynthesis and plant color modification.

Provided are DNA sequences encoding a novel type of AP2 domain-containing transcription factor as well as methods for obtaining similar sequences. Also described are methods for obtaining plants with improved growth and enhanced stress tolerance, particularly tolerance to osmotic and dehydration stress, such methods comprising expression of such DNA sequences in a plant or parts thereof. Further described are diagnostic compositions comprising the aforementioned DNA sequences and the use of such sequences in plant breeding and/or agriculture.

The present invention provides a circular dumbbell oligodeoxynucleotide (CDODN) comprising two loop structures and a stem structure, wherein the stem structure comprises a nucleotide sequence capable of binding the DNA-binding domain of a transcriptional factor. The present invention further provides a pharmaceutical composition comprising said CDODN. The pharmaceutical composition can be used for treating and/or preventing a disease or disorder related to such a transcriptional factor. The present invention also provides a method for treating and/or preventing a disease or disorder related to such a transcriptional factor, comprising administering to the subject a therapeutically effective amount of a CDODN comprising two loop structures and a stem structure, wherein the stem structure comprises a nucleotide sequence capable of binding the DNA-binding domain of the transcriptional factor.

The present invention provides phosphaplatins, stable isolated monomeric phosphate complexes of platinum (II) and (IV), and methods of use thereof for treating cancers, including cisplatin- and carboplatin-resistant cancers. Unlike cisplatin, these complexes do not readily undergo hydrolysis and are quite soluble and stable in aqueous solutions. Moreover, these complexes-unlike cisplatin, carboplatin, and related platinum-based anti-cancer agents-do not bind DNA. Rather, data suggests that phosphaplatins trigger overexpression of fas and fas-related transcription factors and some proapoptotic genes such as Bak and Bax. Nevertheless, the complexes exhibit tremendous cytotoxicity towards cancer cells. Thus, the present invention provides novel platinum anticancer agents that have a different molecular target than those in the art.